Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Sorafenib plus GCLAM yielded 83% complete response rate in AML, MDS

Key clinical point: Sorafenib plus granulocyte colony–stimulating factor, cladribine, high-dose cytarabine, and mitoxantrone appears safe and effective for patients with newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndromes.

Major finding: The complete response rate was 83%; the most common treatment-related adverse event was grade 3 febrile neutropenia, seen in 90% of patients.

Study details: A phase 1 trial of 47 patients with acute myeloid leukemia or myelodysplastic syndromes age 60 years and younger.

Disclosures: The trial was sponsored by the University of Washington, Seattle, in collaboration with the National Cancer Institute, and funding was provided by Bayer. The researchers reported no conflicts of interest.